NEXENTIS TECHNOLOGIES INC. Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $61.56 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Shareholders' Equity
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2021-08-16
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2021-06-30 was $61.56K, a 66.59% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2021-03-31 was $84.50K, a 138.68% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2020-12-31 was $104.13K, a 46.66% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2020-09-30 was $168.82K, a 103.91% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2020 was $492.62K, a 12.30% increase from fiscal 2019.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2019 was $438.67K, a 468.42% increase from fiscal 2018.
- NEXENTIS TECHNOLOGIES INC. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2018 was $77.17K.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2021-06-30 | $61.56K 10-Q · filed 2021-08-16 | $146.06K derived: sum of 2 quarters · filed 2021-08-16 | $250.19K derived: sum of 3 quarters · filed 2021-08-16 | $419.01K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $84.50K 10-Q · filed 2021-08-16 | $188.63K derived: sum of 2 quarters · filed 2021-08-16 | $357.45K derived: sum of 3 quarters · filed 2021-08-16 | $541.72K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-12-31 | $104.13K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $272.95K derived: sum of 2 quarters · filed 2021-03-29 | $457.22K derived: sum of 3 quarters · filed 2021-08-16 | $492.62K 10-K · filed 2021-03-29 |
| 2020-09-30 | $168.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $353.09K derived: sum of 2 quarters · filed 2021-08-16 | $388.49K 10-Q · filed 2020-11-12 | $583.71K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-06-30 | $184.26K 10-Q · filed 2021-08-16 | $219.67K 10-Q · filed 2020-08-11 | $414.89K derived: sum of 3 quarters · filed 2021-08-16 | $497.68K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $35.40K 10-Q · filed 2021-08-16 | $230.62K derived: sum of 2 quarters · filed 2021-08-16 | $313.42K derived: sum of 3 quarters · filed 2021-08-16 | $406.12K derived: sum of 4 quarters · filed 2021-08-16 |
| 2019-12-31 | $195.22K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $278.01K derived: sum of 2 quarters · filed 2021-03-29 | $370.71K derived: sum of 3 quarters · filed 2021-03-29 | $438.67K 10-K · filed 2021-03-29 |
| 2019-09-30 | $82.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $175.50K derived: sum of 2 quarters · filed 2020-11-12 | $243.45K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $92.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $160.66K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $67.95K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $77.17K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |